Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 24.59B, Biogen(BIIB) trades at $167.85. The stock has a price-to-earnings ratio of 15.28.
As of 2025-11-16, Biogen(BIIB) stock has fluctuated between $163.07 and $169.00. The current price stands at $167.85, placing the stock +2.9% above today's low and -0.7% off the high.
The Biogen(BIIB)'s current trading volume is 2.62M, compared to an average daily volume of 1.95M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $169.00 and a 52-week low of $110.04.
In the last year, Biogen(BIIB) shares hit a 52-week high of $169.00 and a 52-week low of $110.04.
BIIB News
Eisai (ESAIY) and Biogen (BIIB) announced that humanized anti- soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI” has been approved for once every fo...
Biogen reported third quarter 2025 earnings ahead of expectations, with revenue rising to US$2.53 billion and net income reaching US$466.5 million, largely supp...
